Safety and immunogenicity of ChAd63 PfAMA1, MVA PfAMA1 and PfAMA1-C1 adjuvanted with Alhydrogel alone or with CPG 7909

The vaccines consist of inactivated viruses that have been modified, so they cannot reproduce in humans, and also include genetic material for malaria protein AMA1 which is expressed by the malaria parasite during blood stage infection. The vaccines are designed to stimulate an immune response to this malaria protein and thus provide protection against malaria infection. Adjuvants are a crucial component of modern vaccine regimens, increasing the immunogenicity and potency of protein vaccines. In this study we will assess whether virus vector vaccines combined with protein in adjuvant AMA1-C1/Alhydrogel® and CPG 7909 adjuvant (emulsion containing TLR agonist) can induce a stronger and more durable immune response.

Study type: Interventional
Enrollment: 35 participant
Primary purpose: Prevention
Allocation: Non-Randomized
Interventional Model: Parallel assignment
Masking : Open label
NCT number: NCT01351948
Phase: Phase I

Clinical trial registration

Vaccines

Jun 2011 — Mar 2013

United Kingdom